The question of vaccinating the public was one of balancing “risks and benefits,” he added, pointing to factors like cost and potential side effects. There isn’t currently a need for mass vaccination at this stage — though that could change if another serious outbreak takes place, Gao said.
The policy marks China apart from many Western governments, most notably Australia, that have outlined plans to introduce mass public vaccination drives.
China’s reported virus numbers have stayed low since the spring. There have been a few flare-ups — clusters in the northeastern Jilin province in May, an outbreak in Beijing in June, and another in the Xinjiang capital of Urumqi in July — but these were met with immediate lockdown measures and mass testing, and the outbreaks were contained within a few weeks.
Gao cited these brief outbreaks as evidence of China’s effective containment measures. “The facts have proven that we have several magic weapons to respond to the epidemic,” he said, according to China News Service.
Any potential vaccine would instead be prioritized for those on the front lines, he added: medical workers, Chinese nationals working overseas in virus hostpots, and people working in dense, high-risk environments like restaurants, schools or cleaning services.
CNN has reached out to the NHC for further comment.
Global race for a vaccine
China is the world’s largest producer and consumer of vaccines, and can supply more than 1 billion doses of a vaccine annually from 40 manufacturers across the country, according to the 2018-2022 China Human Vaccine Industry Report.
Of the more than 30 vaccines currently in human trials globally, nine are from China — the most from any country. And four of the nine vaccine candidates in late-stage trials are being developed by Chinese companies.
Other countries may follow suit; the Indian health minister said on Sunday that the government was considering granting emergency authorization to Covid-19 vaccine candidates before the completion of Phase 3 trials.
Experts have previously said that vaccination is key for countries like China, where the percentage of infected people within the population is relatively low due to strict containment measures.
But Gao warned on Saturday that vaccine development is still a work in progress, with risks of poor side-effects.
“Since there has never been a Covid-19 vaccine developed before, which makes this case the very first in science, it is possible that it may induce ADE (antibody-dependent enhancement) effects as any other firsts we will possibly face,” he said, according to Global Times.
ADE is when specific antibodies help a virus to enter cells and replicate — basically, when a treatment makes the disease worse.
“Scientific research is a very rigorous process, we need to give scientists a bit more time,” he added.